Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a…